A nuclear complex containing PPARα/RXRα is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function Abstract The expression of genes encoding fatty acid utilization enzymes is coordinately downregulated during the development of cardiac hypertrophy and failure. However, molecular mechanisms that mediate this downregulation are unknown. Peroxisome proliferator-activated receptor (PPAR) response elements (PPREs) have been identified in promoters of many genes involved in fatty acid utilization, where they function as positive regulatory elements. PPARs bind to PPREs as heterodimers with retinoid X receptors (RXRs). Primary cardiac myocytes from neonatal rats were transfected with a reporter construct driven by the C promoter of rat acyl-coenzyme A synthetase (ACS) gene. Stimulation with phenylephrine, a potent inducer of hypertrophy, markedly downregulated the activity of this promoter. By use of electrophoretic mobility-shift assays (EMSAs) using PPRE in the rat ACS promoter as a probe, we found a sequence-specific protein-DNA complex in the nuclear extract from adult rat left ventricular (LV) myocardium. Supershift experiments revealed that this complex was immunoreactive for PPARα and RXRα. We compared the activity of this complex in LV nuclear extracts from Dahl salt-sensitive rats (DSs) with hypertension and control age-matched Dahl salt-resistant rats (DRs). Even at the stage of concentric LV hypertrophy with normal systolic function, the activity of the band was markedly diminished in DSs compared with DRs. However, immunoblot analyses showed no difference in LV expression levels of PPARα or RXRα between DSs and DRs. These findings indicate that a nuclear complex of PPARα/RXRα is present in adult rat LV and is markedly downregulated in the hypertrophied LV from DS rats, which may account for the loss of transcriptional activation. The downregulation of this complex precedes LV systolic dysfunction and is mediated at the posttranslational levels.
Introduction
The mammalian heart alters its energy substrate preference in response to diverse physiologic and pathophysiologic conditions. 1, 2 During the development of cardiac hypertrophy, the chief myocardial energy substrate shifts from fatty acids to glucose. 3, 4 In association with this process, the expression of genes encoding fatty acid utilization enzymes such as acyl-coenzyme A (CoA) synthetase (ACS), acyl-CoA oxidase (ACO), and medium-chain acyl-CoA dehydrogenase (MCAD) is coordinately downregulated. 5, 6 However, the molecular mechanisms responsible for this downregulation are unknown. Recently, Barger et al. delineated an upstream gene regulatory pathway associated with a reduction in the expression of the gene encoding muscle carnitine palmitoyltransferase I (M-CPT I), an enzyme involved in mitochondrial fatty acid uptake, during cardiac hypertrophic growth. 7 Studies are clearly needed to confirm that such a mechanism is also the case with other enzymes involved in fatty acid utilization. In this study, we focused on ACS, a key enzyme that catalyzes the initial reaction in fatty acid metabolism.
The expression of genes encoding fatty acid utilization enzymes is regulated, at least in part, at the level of transcription. [8] [9] [10] Interestingly, upstream DNA sequences of these genes contain conserved consensus elements, termed peroxisome proliferator response elements (PPREs), which are required for their transcriptional activities. PPREs are binding sites of peroxisome proliferator-activated receptors (PPARs), transcription factors that belong to the nuclear receptor superfamily. 11 After activation, PPARs heterodimeterize with retinoid X receptors (RXRs) and bind to PPREs, thereby exerting their effects on gene expression. 12 Among three subtypes designated PPARα, -γ, and -/δ, the α receptor is abundantly expressed in the heart in rodents 13, 14 and plays a critical role in regulating genes involved in fatty acid utilization pathways. 15, 16 These findings suggest that PPARα is a major regulator of myocardial fatty acid utilization pathways and that its reduced activity might be responsible for the downregulated expression of genes encoding fatty acid utilization enzymes. Consistent with this speculation, the downregulated expression of the gene encoding M-CPT I during cardiac hypertrophy has been shown to be linked to deactivation of the PPARα regulatory pathway. 7 According to in vitro experiments, PPAR-mediated activation of target gene transcription requires the formation of a large nuclear complex with transcriptional coactivators bridging between PPAR/RXR and components of basal transcription machinery. However, such a complex has not yet been detected in adult rat left ventricular myocardium in vivo, and it is not known how it is involved in the regulation of its target genes in pathophysiologic processes, such as cardiac hypertrophy. In this study, we demonstrate the presence of a nuclear complex containing PPARα and RXRα in adult rat myocardial tissue in vivo by electrophoretic mobility-shift assays (EMSAs) using a synthetic oligonucleotide containing PPRE in the heart-specific C promoter of rat ACS gene as a probe. Furthermore, we report here that the PPARα/RXRα complex is markedly downregulated in the hypertrophied heart form Dahl saltsensitive (DS) rats, which develop cardiac hypertrophy when fed a high-salt diet. 17 
Materials and methods

Cell culture
Primary ventricular cardiac myocytes were prepared as described previously. 18 Briefly, hearts from 1-2-day-old Sprague-Dawley rats were removed, the ventricles were pooled, and the ventricular cells were dispersed by digestion with pancreatin (Gibco BRL, Gaithersburg, MD, USA). The cells were preplated for 1 h to enrich for myocytes (90%-95%) of the cells after this step). Cells were plated at a density of 250 cells/mm 2 onto 60-mm tissue culture dishes (Primaria, Falcon; Becton Dickinson, Franklin Lakes, NJ, USA) and cultured in medium consisting of Hank's salts plus minimal essential medium (MEM) vitamin stock, MEM amino acids, MEM nonessential amino acids, 2 mM l-glutamine, 0.67 mM glycine, 0.92 mM hypoxanthine, 19.6 mM NaHCO 3 (pH 7.1-7.2), penicillin, streptomycin, and 10% (v/v) fetal bovine serum (FBS) (all from Gibco BRI) at 37°C, 5% CO 2 for 24 h.
Plasmid constructs
The plasmid construct pACS-CAT was the transcription start site-proximal 961-bp wild-type C promoter of rat acylcoenzyme A synthetase (ACS) gene fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. 8 This plasmid was a gift from Dr. J. Auwerx, Institut Pasteur, Lille, France. pRSVluc contains a luciferase gene driven by Rous sarcoma virus (RSV) long terminal repeat sequences. Plasmids were purified by anion exchange chromatography (Qiagen, Hilden, Germany), quantified by measurement of OD 260 , and examined on agarose gels stained with ethidium bromide prior to use.
Transfection and luciferase/CAT assays Twenty-four hours after plating, the cells were washed twice with serum-free medium and then cotransfected with 1 µg of pACS-CAT, 0.1 µg of pRSVluc using LipofectaminePlus (Gibco BRL) according to the manufacturer's recommendation. After a 2-h incubation with DNA-lipofectamine complex, the cells were washed twice with serum-free media and further incubated for 48 h in serum-free medium in the presence of phenylephrine (1.0 ϫ 10 Ϫ5 M) or saline as controls. The cells were then washed twice with ice-cold PBS, lysed with lysis buffer and subjected to assays for luciferase and CAT activities, as described previously. 18 Experimental animals and in vivo assessment of left ventricular geometry and function Male inbred Dahl salt-sensitive (DS) and salt-resistant (DR) rats, obtained from Brookhaven National Laboratories (Upton, NY, USA), were further bred and supplied by Eisai (Tokyo, Japan). 19 The rats were fed a 0.3% NaCl (lowsalt) diet after weaning until the age of 6 weeks, after which they were fed an 8% NaCl (high-salt) diet. Systolic blood pressure of each animal was measured by a tail-cuff method on the day before sacrifice. On the same day, left ventricular dimensions and contractile function were evaluated in vivo using transthoracic echocardiography as previously reported in detail. 20 Electrophoretic mobility-shift assays Nuclear extracts were prepared from adult rat ventricular myocardium as previously described. 21 Double-stranded oligonucleotides that contained PPRE from the rat C-ACS or the rat ACO promoters were designed. The sequences of the sense strand of these oligonucleotides were as follows: C-ACSwt, 5Ј-GATCCGGCATGTGACTGATGCCCTG AAAGACCTTGGCAGGA-3Ј; C-ACSmut, 5Ј-GATCCG GCATGCAGCTGGGGCCCTGAAAGACCTTGGCAGGA-3Ј; ACO, 5Ј-GATCCCGAACGTGACCTTTGTCCTGG TCCC-3Ј. We also used a double-stranded oligonucleotide that contained a p53 binding site in the p21 promoter as a control probe. 22 Oligonucleotides were synthesized by Greiner (Tokyo, Japan) and purified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SAS-PAGE). EMSAs were carried out in 10 µg of nuclear extracts, as previously described. 22 Oligonucleotides were end-labeled with [γ-32 P]ATP (Amersham, Uppsala, Sweden) by T4 polynucleotide kinase (Takara, Kyoto, Japan). DNA-protein complexes were separated by electrophoresis on 4% nondenaturing polyacrylamide gels in 0.25 ϫ TBE (1 ϫ TBE is 100 mM Tris, 100 mM boric acid, and 2 mM EDTA) at 4°C. Specificity was confirmed by the addition of 100 molar excess of an unlabeled wild-type (wt) or mutated (mut) oligonucleotide to the binding reaction mixture. For supershift studies, the following antibodies were purchased: polyclonal goat anti-PPARα antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit anti-RXRα antibody (Santa Cruz).
Western blot analysis
Nuclear extracts identical to those used in EMSAs were applied to 10% SDS-PAGE, transferred to nitrocellulose membranes (Amersham), incubated with TBS-Tween/5% dry milk overnight and reacted with a goat polyclonal antibody against PPARα (Santa Cruz) and a rabbit polyclonal antibody against RXRα (Santa Cruz). After washing, the membranes were incubated with horseradish peroxidaseconjugated secondary antibodies and detected with the enhanced chemiluminescence system (Amersham).
Statistical analysis
Data are presented as mean Ϯ SE. Statistical comparisons were performed using unpaired two-tailed Student's t-test or analysis of variance with Scheffé's test when appropriate, with a probability value of less than 0.05 taken to indicate significance.
Results
Hypertrophic stimulus markedly downregulates the C-ACS promoter activity in neonatal rat cardiac myocytes
The expression of genes encoding fatty acid utilization enzymes is coordinately downregulated in hypertrophied hearts. To determine whether transcriptional mechanisms are involved in this process, the CAT cDNA driven by the proximal 961-bp C promoter of rat ACS gene was transfected into neonatal rat cardiac myocytes in culture. To control for transfection efficiency, the cells were cotransfected with a small quantity of pRSVluc. After 48 h of stimulation with phenylephrine (1.0 ϫ 10 Ϫ5 M) or saline as a control, cardiomyocytes were harvested for luciferase and CAT assays. As shown in Fig. 1 , stimulation with an α1-adrenergic agonist, phenylephrine, a representative hypertrophic stimulus, markedly downregulated the activity of the C-ACS promoter. However, phenylephrine stimulus did not reduce the activity of a promoter derived from the ubiquitously expressed -action gene (data not shown). These findings demonstrate that the proximal 961-bp rat C-ACS promoter sequence contains element(s) that mediate downregulation of this gene in response to phenylephrine stimulation in cardiac myocytes.
A nuclear complex containing PPARα and RXRα is present in adult rat left ventricular myocardium The C-ACS promoter contains a putative PPRE, which functions as a positive regulatory element. To detect cardiac nuclear factor(s) that bind to the PPRE, EMSAs were performed using nuclear extracts prepared from left ventricular myocardium of adult male Wistar rats. As shown in Fig. 2A , incubation of the nuclear extract with the radiolabeled oligonucleotide containing the C-ACS PPRE revealed multiple bands with different mobilities (Fig. 2A,  lane 1) . Among these, a band with the lowest mobility (indicated by an arrow) was made competitive by 100-fold molar excess of unlabeled C-ACS PPRE oligonucleotide (Fig. 2A, lane 2, wt) , but not by unlabeled C-ACS PPRE oligonucleotide with a mutation in its core PPRE sequence (Fig. 2A, lane 4, mut) . These findings indicate that this band represents a sequence-specific interaction of cardiac nuclear extracts with this probe. This complex was also made competitive by the addition of unlabeled oligonucleotide containing the PPRE in the rat ACO promoter (Fig. 2A, lane  3) , another putative binding site of PPARs. In addition, coincubation of the protein-DNA mixture with an anti-PPARα antibody, but not with control IgG, resulted in the disappearance of this band (Fig. 2B, lane 2) , indicating the existence of PPARα in this complex. In another set of experiments it was confirmed that this band reacted with anti-PPARα antibody; thus, it contains PPARα. Furthermore, we examined whether this complex also contains RXRα, a To determine if the PPRE binding activity is modulated during cardiac hypertrophy following pressure overload, the C-ACS PPRE probe was incubated with nuclear extracts from left ventricular myocardium of Dahl saltsensitive (DS) rats with hypertension and control age-matched Dahl salt-resistant (DR) rats. DS rats fed with a high-salt diet developed systemic hypertension (Ͼ220 mmHg). At the age of 11 weeks, the left ventricular mass to body weight ratio was 50% greater in DS rats compared with the age-matched DR rats. Echocardiographic data demonstrated that the wall thickness was more than 20% greater in DSs compared with age-matched DRs. However, left ventricular fractional shortening tended to be higher in DSs than in DRs, implying the established mechanical compensation for the increased afterload. These data are consistent with our previous reports and show the development of compensatory left ventricular hypertrophy at the age of 11 weeks in this animal model. As shown in Fig.   3A , the activity of the PPAR/RXRα complex was much lower in nuclear extracts from the hypertrophied left ventricular myocardium of the 11-week-old DS rats compared with those from the normal left ventricular myocardium of the 11-week-old DR rats. In contrast, p53 binding activities in left ventricular myocardium did not differ between DS and DR rats (Fig. 3B) .
To determine whether the diminished activity of the PPARα/RXRα complex was attributable to decreased expression of its component proteins, immunoblot analyses were performed using nuclear extracts identical to those used for EMSAs. As shown in Fig. 4 , the expression of Fig. 2A,B . Electrophoretic mobility-shift assay of cardiac nuclear extracts from normal adult rats. A Synthetic double-stranded oligonucleotide containing the rat C-ACS peroxisome proliferator response element (PPRE) was end-labeled with 32 P and incubated with nuclear extracts from normal left ventricular myocardial tissue of adult Wistar rats. The reaction was then analyzed by gel electrophoresis, followed by autoradiography. Competition was performed with 100-fold molar excess of the wild-type (lane 2) or the mutated (lane 4) C-ACS PPRE oligonucleotide. Cross-competition was conducted using the rat acyl-coenzyme A oxidase (ACO) PPRE oligonucleotide (lane 3). B Supershift studies were performed. Control IgG (lane 1) or an antibody against peroxisome proliferator-activated receptor (PPAR)α (lane 2) and retinoid ϫ receptor (RXR)α (lane 3) was preincubated with nuclear extracts before the addition of the labeled C-ACS PPRE oligonucleotide Fig. 3A,B . Electrophoretic mobility-shift assay of the PPARα/RXRα complex in the left ventricular myocardial tissues from Dahl saltsensitive (DS) and Dahl salt-resistant (DR) rats. The complex was markedly downregulated in the nuclear extracts from the hypertrophied left ventricular myocardium of the 11-week-old DSs compared with those from the normal left ventricular myocardium of the agematched DRs. The C-ACS PPRE oligonucleotide (A) or an oligonucleotide containing a p53 binding site in the p21 promoter (B) was radiolabeled, incubated with the cardiac nuclear extracts from the 11-week-old DRs (lanes 1 and 2) or those from the age-matched DSs (lanes 3 and 4) , and then analyzed by gel electrophoresis Fig. 4 . Western blot analyses of the expression levels of PPARα and RXRα in the normal and hypertrophied left ventricular myocardium from DRs and DSs, respectively. Nuclear extracts identical to those used in Fig. 3 were also used in these experiments. Antibodies against PPARα and RXRα were used primary antibodies. Horseradish peroxidase-conjugated antibodies were used as secondary antibodies. The activity was visualized with the enhanced chemiluminescence system PPARα or RXRα did not differ between DRs and DSs. These findings suggest that the marked downregulation of the PPARα/RXRα complex is mediated at the posttranslational levels.
Discussion
During the development of cardiac hypertrophy, the chief myocardial energy substrate switches from fatty acids to glucose, which may represent a reversal to the fetal energy substrate preference pattern. In association with this process, the expression of genes involved in fatty acid utilization pathways is coordinately downregulated. The present study investigated the molecular mechanisms that mediate this downregulation. The major findings are (1) hypertrophic stimulus markedly downregulates the C-ACS promoter activity in neonatal rat cardiac myocytes, and (2) a nuclear complex containing PPARα and RXRα is present in adult rat left ventricular myocardium and is markedly downregulated in the hypertrophied left ventricular myocardium with normal systolic function. These findings provide further insight into the gene regulatory pathway involved in the energy substrate switch during cardiac hypertrophy.
An α1-adrenergic agonist, phenylephrine, is a potent inducer of myocardial cell hypertrophy in culture. Despite the existence of several limitations, hypertrophy induced by this stimulus mimics pressure overload-induced hypertrophy in adult left ventricular myocardium in vivo. The present study demonstrated that stimulation of cardiac myocytes with phenylephrine markedly downregulated the activity of the transfected C-ACS promoter. This finding is consistent with a previous study using other PPARα response elements, including FARE-1 derived from the human M-CPT I promoter. 7 Compatible with these in vitro findings, in vivo ventricular pressure overload studies performed in transgenic mice for human MCAD promoter fragments linked to reporter genes have shown that the reporter expression is markedly downregulated within 7 days of pressure overload. 23, 24 Thus, reduction in promotor activities is not confined to in vitro assays in neonatal cells, but may also occur in adult cardiac myocytes in vivo. These findings suggest that the downregulated expression of genes involved in fatty acid utilization pathways in hypertrophied hearts is mediated, at least in part, at the level of transcription.
PPARs are nuclear receptors that play key roles in transcriptional regulation of genes involved in fatty acid utilization pathways. PPAR-responsive elements (PPREs) are conserved in many genes involved in fatty acid utilization, including ACS, ACO, and MCAD, where they function as positive regulatory elements. [8] [9] [10] We found that PPRE binding activities are markedly reduced in hypertrophied left ventricular myocardium with normal systolic function. This is compatible with previously reported findings that the expression of genes involved in fatty acid utilization pathways is downregulated in left ventricular myocardium with compensated hypertrophy in spontaneously hypertensive rats and in rats following pressure overload. 5, 24 Taken together, our results suggest that the reduced expression of genes encoding fatty acid utilization enzymes in the hypertrophied heart is attributable, in part, to loss of PPAR activation or maintenance of expression and that these molecular events precede left ventricular systolic dysfunction. Naturally, it is possible that other mechanisms are involved. Active transcriptional repression by some repressor proteins is a likely mechanism to be studied in future investigations. A previous study 7 has suggested that chicken ovalbumin upstream promotor transcription factor (COUP-TF) is one of the candidate factors responsible for the possible transcriptional repression of genes encoding fatty acid utilization enzymes during cardiac hypertrophy. We are now considering conducting experiments to determine whether COUP-TF expression is upregulated also in our hypertrophy model. However, it was reported that the immunoreactive levels of these enzymes in left ventricular myocardium were not reduced at the compensated stage but reduced only at the heart failure stage. 5, 24 Thus, additional mechanisms at the translational or posttranslational levels may maintain the expression of these enzymes in left ventricular myocardium with compensated hypertrophy. 7, 25 Activated PPAR binds to RXR and forms a heterodimer. The present study demonstrated that cardiac nuclear factors that bound PPRE were immunoreactive for RXRα as well as PPARα. These findings suggest that these two proteins form a nuclear complex in adult rat left ventricular myocardium. Interstingly, despite the marked downregulation of this complex in left ventricular myocardium with compensated hypertrophy, the expression of its component PPARα and RXRα was not reduced. These findings suggest that posttranslational mechanisms are involved in the downregulation of this complex. One possible mechanism is that the altered phosphorylation state of PPARα may reduce its ability to interact with RXR and PPRE. Since the downregulation of the PPARα/RXRα complex might be an initial predisposing step leading to the energy substrate switch during cardiac hypertrophy and failure, it would be of particular interest to further clarify the precise mechanisms that mediate the downregulation of this complex.
